EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives
A Addeo, E Miranda-Morales, P den Hollander… - Pharmacology & …, 2023 - Elsevier
Precision oncology informed by genomic information has evolved in leaps and bounds over
the last decade. Although non-small cell lung cancer (NSCLC) has moved to center-stage as …
the last decade. Although non-small cell lung cancer (NSCLC) has moved to center-stage as …
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
Epithelial–mesenchymal transition (EMT) is an important process for cancer metastasis,
drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 …
drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 …
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
High expression or aberrant activation of epidermal growth factor receptor (EGFR) is related
to tumor progression and therapy resistance across cancer types, including non-small cell …
to tumor progression and therapy resistance across cancer types, including non-small cell …
FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance
J Szymczyk, KD Sluzalska, I Materla, L Opalinski… - Cancers, 2021 - mdpi.com
Simple Summary Deregulation of the FGF/FGFR axis is associated with many types of
cancer and contributes to the development of chemoresistance, limiting the effectiveness of …
cancer and contributes to the development of chemoresistance, limiting the effectiveness of …
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
T Shaurova, L Zhang, DW Goodrich… - Frontiers in …, 2020 - frontiersin.org
Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …
The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
ABSTRACT Fibroblast Growth Factor (FGF) ligands and their receptors are crucial factors
driving chemoresistance in several malignancies, challenging the efficacy of currently …
driving chemoresistance in several malignancies, challenging the efficacy of currently …
Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of MET
EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–
small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of …
small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of …
[HTML][HTML] MicroRNAs associated with therapy of non-small cell lung cancer
J Lu, Y Zhan, J Feng, J Luo, S Fan - International Journal of …, 2018 - ncbi.nlm.nih.gov
Background & Objective: The incidence of non-small cell lung cancer (NSCLC) has been
rising over the past several decades. Despite various therapeutic regimens and modern …
rising over the past several decades. Despite various therapeutic regimens and modern …
Mitochondria-targeting fluorescent molecules for high efficiency cancer growth inhibition and imaging
H Chen, J Wang, X Feng, M Zhu, S Hoffmann… - Chemical …, 2019 - pubs.rsc.org
Fluorescent mitochondria-accumulating delocalized lipophilic cations (DLCs) for cancer
therapy have drawn significant attention in the field of cancer theranostics. One of the most …
therapy have drawn significant attention in the field of cancer theranostics. One of the most …